SGLT2 Inhibitors As a Therapeutic Option for Diabetic Nephropathy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2017 May 20

PMID 28524098

Citations 56

Authors

Daiji Kawanami

Keiichiro Matoba

Yusuke Takeda

Yosuke Nagai

Tomoyo Akamine

Tamotsu Yokota

Kazunori Sango

Kazunori Utsunomiya

Affiliations

Soon will be listed here.

Abstract

Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the incidence and progression of DN. Sodium-glucose cotransporter (SGLT) 2 inhibitors are a new class of glucose-lowering agent suggested to exert renoprotective effects in glucose lowering-dependent and independent fashions. Experimental studies have shown that SGLT2 inhibitors attenuate DN in animal models of both type 1 diabetes (T1D) and type 2 diabetes (T2D), indicating a potential renoprotective effect beyond glucose reduction. Renoprotection by SGLT2 inhibitors has been demonstrated in T2D patients with a high cardiovascular risk in randomized controlled trials (RCTs). These favorable effects of SGLT2 inhibitors are explained by several potential mechanisms, including the attenuation of glomerular hyperfiltration, inflammation and oxidative stress. In this review article, we discuss the renoprotective effects of SGLT2 inhibitors by integrating experimental findings with the available clinical data.

Citing Articles

Advances in kidney disease: pathogenesis and therapeutic targets.

Boima V, Agyekum A, Ganatra K, Agyekum F, Kwakyi E, Inusah J Front Med (Lausanne). 2025; 12:1526090.

PMID: 40027896 PMC: 11868101. DOI: 10.3389/fmed.2025.1526090.

Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors.

Mederle A, Dumitrescu P, Borza C, Kundnani N J Clin Med. 2025; 14(1.

PMID: 39797270 PMC: 11721703. DOI: 10.3390/jcm14010188.

Breaking boundaries in diabetic nephropathy treatment: design and synthesis of novel steroidal SGLT2 inhibitors.

Nongthombam G, Ahmed S, Saikia K, Gogoi S, Borah J RSC Med Chem. 2024; .

PMID: 39479473 PMC: 11514366. DOI: 10.1039/d4md00645c.

Impact of Empagliflozin on the Outcomes of β-Thalassemia Major in Patients With Type 2 Diabetes Mellitus: The THALEMPA Observational Study.

Ibraheem A, Al Tameemi W Cureus. 2024; 16(9):e69837.

PMID: 39435207 PMC: 11492160. DOI: 10.7759/cureus.69837.

Plasma angiotensin-converting enzyme 2 (ACE2) is a marker for renal outcome of diabetic kidney disease (DKD) (U-CARE study 3).

Ueno A, Onishi Y, Mise K, Yamaguchi S, Kanno A, Nojima I BMJ Open Diabetes Res Care. 2024; 12(3).

PMID: 38816205 PMC: 11141182. DOI: 10.1136/bmjdrc-2024-004237.

References

Aizawa K, Takeda S, Tashiro Y, Yorozu K, Hirata M, Kanada H . Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome. Am J Nephrol. 2012; 36(5):419-26. DOI: 10.1159/000343493. View

Neal B, Perkovic V, de Zeeuw D, Mahaffey K, Fulcher G, Stein P . Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J. 2013; 166(2):217-223.e11. DOI: 10.1016/j.ahj.2013.05.007. View

Tsuruya K, Yoshida H, Suehiro T, Fujisaki K, Masutani K, Kitazono T . Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin. Ren Fail. 2016; 38(3):390-6. DOI: 10.3109/0886022X.2015.1136874. View

Vallon V, Gerasimova M, Rose M, Masuda T, Satriano J, Mayoux E . SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2013; 306(2):F194-204. PMC: 3920018. DOI: 10.1152/ajprenal.00520.2013. View

Goto A, Arah O, Goto M, Terauchi Y, Noda M . Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013; 347:f4533. DOI: 10.1136/bmj.f4533. View

Jalal D, Maahs D, Hovind P, Nakagawa T . Uric acid as a mediator of diabetic nephropathy. Semin Nephrol. 2011; 31(5):459-65. PMC: 3197214. DOI: 10.1016/j.semnephrol.2011.08.011. View

Ma Q, Steiger S, Anders H . Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. Physiol Rep. 2017; 5(7). PMC: 5392518. DOI: 10.14814/phy2.13228. View

Ito D, Ikuma-Suwa E, Inoue K, Kaneko K, Yanagisawa M, Inukai K . Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study. J Clin Med Res. 2017; 9(2):154-162. PMC: 5215019. DOI: 10.14740/jocmr2875w. View

Panchapakesan U, Pegg K, Gross S, Gangadharan Komala M, Mudaliar H, Forbes J . Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?. PLoS One. 2013; 8(2):e54442. PMC: 3563635. DOI: 10.1371/journal.pone.0054442. View

10.

Sano M, Takei M, Shiraishi Y, Suzuki Y . Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys. J Clin Med Res. 2016; 8(12):844-847. PMC: 5087622. DOI: 10.14740/jocmr2760w. View

11.

Kawanami D, Matoba K, Utsunomiya K . Signaling pathways in diabetic nephropathy. Histol Histopathol. 2016; 31(10):1059-67. DOI: 10.14670/HH-11-777. View

12.

Novikov A, Vallon V . Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr Opin Nephrol Hypertens. 2015; 25(1):50-8. PMC: 4703043. DOI: 10.1097/MNH.0000000000000187. View

13.

Vallon V, Platt K, Cunard R, Schroth J, Whaley J, Thomson S . SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2010; 22(1):104-12. PMC: 3014039. DOI: 10.1681/ASN.2010030246. View

14.

Cherney D, Perkins B, Soleymanlou N, Har R, Fagan N, Johansen O . The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014; 13:28. PMC: 3915232. DOI: 10.1186/1475-2840-13-28. View

15.

Mogensen C . Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest. 1971; 28(1):101-9. DOI: 10.3109/00365517109090668. View

16.

Thomson S, Vallon V, Blantz R . Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol. 2003; 286(1):F8-15. DOI: 10.1152/ajprenal.00208.2003. View

17.

Abdul-Ghani M, Norton L, DeFronzo R . Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011; 32(4):515-31. DOI: 10.1210/er.2010-0029. View

18.

Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S . Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis. Horm Metab Res. 2015; 47(9):686-92. DOI: 10.1055/s-0034-1395609. View

19.

Lytvyn Y, Skrtic M, Yang G, Yip P, Perkins B, Cherney D . Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2014; 308(2):F77-83. DOI: 10.1152/ajprenal.00555.2014. View

20.

Cherney D, Perkins B, Soleymanlou N, Maione M, Lai V, Lee A . Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2013; 129(5):587-97. DOI: 10.1161/CIRCULATIONAHA.113.005081. View